Publications by authors named "Fiona Blackhall"

100Publications

Aprepitant For Cough in Lung Cancer: A Randomised Placebo-Controlled Trial and Mechanistic Insights.

Am J Respir Crit Care Med 2020 Sep 23. Epub 2020 Sep 23.

The University of Manchester, 5292, Division of Molecular & Clinical Cancer Sciences, Manchester, United Kingdom of Great Britain and Northern Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1164/rccm.202006-2359OCDOI Listing
September 2020

The Rare YAP1 Subtype of SCLC Revisited in a Biobank of 39 Circulating Tumor Cell Patient Derived Explant Models: A Brief Report.

J Thorac Oncol 2020 Jul 25. Epub 2020 Jul 25.

Cancer Research UK Manchester Institute Cancer Biomarker Centre, University of Manchester, Manchester, United Kingdom; Cancer Research UK Lung Cancer Centre of Excellence, Manchester, United Kingdom; Division of Cancer Sciences, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, United Kingdom. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2020.07.008DOI Listing
July 2020

Direct Ras G12C inhibitors: crossing the rubicon.

Br J Cancer 2019 07 26;121(3):197-198. Epub 2019 Jun 26.

Division of Molecular and Clinical Cancer Sciences, University of Manchester, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0499-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738074PMC
July 2019

Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily Versus Twice-Daily Radiotherapy (CONVERT) Trial.

J Thorac Oncol 2019 01 31;14(1):63-71. Epub 2018 Oct 31.

Department of Radiotherapy Related Research, The Christie NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864183318
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2018.09.027DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328625PMC
January 2019

Cough in Patients With Lung Cancer: A Longitudinal Observational Study of Characterization and Clinical Associations.

Chest 2019 01 13;155(1):103-113. Epub 2018 Oct 13.

Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, England; Manchester University NHS Foundation Trust, Manchester, England.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.chest.2018.10.003DOI Listing
January 2019

Will liquid biopsies improve outcomes for patients with small-cell lung cancer?

Lancet Oncol 2018 09;19(9):e470-e481

Clinical and Experimental Pharmacology Group and Manchester Centre for Cancer Biomarker Sciences, Cancer Research UK Manchester Institute, University of Manchester, Manchester, UK; Cancer Research UK Lung Cancer Centre of Excellence at University College London, London, UK; University of Manchester, Manchester, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30455-8DOI Listing
September 2018

A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group.

J Thorac Dis 2018 Jul;10(7):3909-3921

Department of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2018.07.61DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6106007PMC
July 2018

Investigation of myositis and scleroderma specific autoantibodies in patients with lung cancer.

Arthritis Res Ther 2018 08 9;20(1):176. Epub 2018 Aug 9.

Centre for Epidemiology, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13075-018-1678-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6085683PMC
August 2018

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.

J Clin Oncol 2018 08 16;36(22):2251-2258. Epub 2018 May 16.

Benjamin J. Solomon, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Dong-Wan Kim, Seoul National University Hospital, Seoul, Republic of Korea; Yi-Long Wu, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou; Tony S. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; Kazuhiko Nakagawa, Kindai University Faculty of Medicine, Osaka, Japan; Tarek Mekhail, Florida Hospital, Orlando, FL; Enriqueta Felip, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Federico Cappuzzo, Azienda Unità Sanitaria Locale Della Romagna, Ravenna; Jolanda Paolini and Tiziana Usari, Pfizer Oncology, Milan, Italy; Yiyun Tang and Keith D. Wilner, Pfizer Oncology, La Jolla, CA; and Fiona Blackhall, Manchester University, and Christie Hospital National Health Service Foundation Trust, Manchester, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.4794DOI Listing
August 2018

Is heterogeneity in stage 3 non-small cell lung cancer obscuring the potential benefits of dose-escalated concurrent chemo-radiotherapy in clinical trials?

Lung Cancer 2018 04 14;118:139-147. Epub 2018 Feb 14.

Division of Molecular and Clinical Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK; Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2018.02.006DOI Listing
April 2018

Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.

Authors:
Christopher Abbosh Nicolai J Birkbak Gareth A Wilson Mariam Jamal-Hanjani Tudor Constantin Raheleh Salari John Le Quesne David A Moore Selvaraju Veeriah Rachel Rosenthal Teresa Marafioti Eser Kirkizlar Thomas B K Watkins Nicholas McGranahan Sophia Ward Luke Martinson Joan Riley Francesco Fraioli Maise Al Bakir Eva Grönroos Francisco Zambrana Raymondo Endozo Wenya Linda Bi Fiona M Fennessy Nicole Sponer Diana Johnson Joanne Laycock Seema Shafi Justyna Czyzewska-Khan Andrew Rowan Tim Chambers Nik Matthews Samra Turajlic Crispin Hiley Siow Ming Lee Martin D Forster Tanya Ahmad Mary Falzon Elaine Borg David Lawrence Martin Hayward Shyam Kolvekar Nikolaos Panagiotopoulos Sam M Janes Ricky Thakrar Asia Ahmed Fiona Blackhall Yvonne Summers Dina Hafez Ashwini Naik Apratim Ganguly Stephanie Kareht Rajesh Shah Leena Joseph Anne Marie Quinn Phil A Crosbie Babu Naidu Gary Middleton Gerald Langman Simon Trotter Marianne Nicolson Hardy Remmen Keith Kerr Mahendran Chetty Lesley Gomersall Dean A Fennell Apostolos Nakas Sridhar Rathinam Girija Anand Sajid Khan Peter Russell Veni Ezhil Babikir Ismail Melanie Irvin-Sellers Vineet Prakash Jason F Lester Malgorzata Kornaszewska Richard Attanoos Haydn Adams Helen Davies Dahmane Oukrif Ayse U Akarca John A Hartley Helen L Lowe Sara Lock Natasha Iles Harriet Bell Yenting Ngai Greg Elgar Zoltan Szallasi Roland F Schwarz Javier Herrero Aengus Stewart Sergio A Quezada Karl S Peggs Peter Van Loo Caroline Dive C Jimmy Lin Matthew Rabinowitz Hugo J W L Aerts Allan Hackshaw Jacqui A Shaw Bernhard G Zimmermann Charles Swanton

Nature 2018 02 20;554(7691):264. Epub 2017 Dec 20.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature25161DOI Listing
February 2018

Targeting DNA damage in SCLC.

Lung Cancer 2017 12 16;114:12-22. Epub 2017 Oct 16.

Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK; Institute of Cancer Sciences, University of Manchester, Manchester, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2017.10.006DOI Listing
December 2017

Is it time to convert the frequency of radiotherapy in small-cell lung cancer? - Authors' reply.

Lancet Oncol 2017 10;18(10):e556

Division of Molecular and Clinical Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9PL, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30611-3DOI Listing
October 2017

The clinical utility of circulating tumour cells in patients with small cell lung cancer.

Transl Lung Cancer Res 2017 Aug;6(4):409-417

Institute of Cancer Sciences, CRUK Manchester Institute, University of Manchester, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tlcr.2017.07.05DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583068PMC
August 2017

Circulating tumor cells and CDX models as a tool for preclinical drug development.

Transl Lung Cancer Res 2017 Aug;6(4):397-408

Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, UK.

View Article

Download full-text PDF

Source
http://tlcr.amegroups.com/article/view/14974/12187
Publisher Site
http://dx.doi.org/10.21037/tlcr.2017.08.01DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583071PMC
August 2017

Spotlight on circulating tumour cells.

Transl Lung Cancer Res 2017 Aug;6(4):396

Cancer Research UK Lung Cancer Centre of Excellence, CRUK Manchester Institute, University of Manchester, Manchester, UK. (Email:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tlcr.2017.08.05DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583069PMC
August 2017

Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial.

J Thorac Oncol 2017 10 24;12(10):1588-1594. Epub 2017 Jul 24.

Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.07.011DOI Listing
October 2017

What do we need to make circulating tumour DNA (ctDNA) a routine diagnostic test in lung cancer?

Eur J Cancer 2017 08 10;81:66-73. Epub 2017 Jun 10.

Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK; Division of Molecular and Clinical Cancer Sciences, University of Manchester, Manchester, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.04.022DOI Listing
August 2017

Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.

Authors:
Christopher Abbosh Nicolai J Birkbak Gareth A Wilson Mariam Jamal-Hanjani Tudor Constantin Raheleh Salari John Le Quesne David A Moore Selvaraju Veeriah Rachel Rosenthal Teresa Marafioti Eser Kirkizlar Thomas B K Watkins Nicholas McGranahan Sophia Ward Luke Martinson Joan Riley Francesco Fraioli Maise Al Bakir Eva Grönroos Francisco Zambrana Raymondo Endozo Wenya Linda Bi Fiona M Fennessy Nicole Sponer Diana Johnson Joanne Laycock Seema Shafi Justyna Czyzewska-Khan Andrew Rowan Tim Chambers Nik Matthews Samra Turajlic Crispin Hiley Siow Ming Lee Martin D Forster Tanya Ahmad Mary Falzon Elaine Borg David Lawrence Martin Hayward Shyam Kolvekar Nikolaos Panagiotopoulos Sam M Janes Ricky Thakrar Asia Ahmed Fiona Blackhall Yvonne Summers Dina Hafez Ashwini Naik Apratim Ganguly Stephanie Kareht Rajesh Shah Leena Joseph Anne Marie Quinn Phil A Crosbie Babu Naidu Gary Middleton Gerald Langman Simon Trotter Marianne Nicolson Hardy Remmen Keith Kerr Mahendran Chetty Lesley Gomersall Dean A Fennell Apostolos Nakas Sridhar Rathinam Girija Anand Sajid Khan Peter Russell Veni Ezhil Babikir Ismail Melanie Irvin-Sellers Vineet Prakash Jason F Lester Malgorzata Kornaszewska Richard Attanoos Haydn Adams Helen Davies Dahmane Oukrif Ayse U Akarca John A Hartley Helen L Lowe Sara Lock Natasha Iles Harriet Bell Yenting Ngai Greg Elgar Zoltan Szallasi Roland F Schwarz Javier Herrero Aengus Stewart Sergio A Quezada Karl S Peggs Peter Van Loo Caroline Dive C Jimmy Lin Matthew Rabinowitz Hugo J W L Aerts Allan Hackshaw Jacqui A Shaw Bernhard G Zimmermann Charles Swanton

Nature 2017 04;545(7655):446-451

Cancer Research UK Lung Cancer Centre of Excellence London and Manchester, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6DD, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature22364DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5812436PMC
April 2017

Tracking the Evolution of Non-Small-Cell Lung Cancer.

N Engl J Med 2017 06 26;376(22):2109-2121. Epub 2017 Apr 26.

From the Cancer Research UK Lung Cancer Centre of Excellence (M.J.-H., G.A.W., N. McGranahan, N.J.B., S.V., S.S., D.H.J., R.R., S.-M.L., M.D.F., C.A., S.M.J., C.D., C.S.), London and Manchester, Good Clinical Laboratory Practice Facility, University College London (UCL) Experimental Cancer Medicine Centre (H.L.L., J.A.H.), Bill Lyons Informatics Centre (J.H.), and Cancer Immunology Unit (S.A.Q.), UCL Cancer Institute, the Translational Cancer Therapeutics Laboratory (G.A.W., N. McGranahan, N.J.B., T.B.K.W., A.R., T.C., S. Turajlic, H.X., C.T.H., C.S.), Department of Bioinformatics and Biostatistics (R.M., M.S., S.H., M.E., A.S.), Advanced Sequencing Facility (N. Matthews), and Cancer Genomics Laboratory (S.D., P.V.L.), Francis Crick Institute, the Renal and Skin Units, Royal Marsden Hospital (S. Turajlic), the Departments of Medical Oncology (M.J.-H., S.-M.L., M.D.F., T.A., C.A., C.S.), Pathology (M.F., E.B., T.M.), Cardiothoracic Surgery (D.L., M.H., S. Kolvekar, N.P.), Respiratory Medicine (S.M.J., R.T.), and Radiology (A.A.), UCL Hospitals, Lungs for Living, UCL Respiratory, UCL (S.M.J.), the Department of Radiotherapy, North Middlesex University Hospital (G.A.), the Department of Respiratory Medicine, Royal Free Hospital (S. Khan), and UCL Cancer Research UK and Cancer Trials Centre (N.I., H.B., Y.N., A.H.), London, Cancer Studies, University of Leicester (D.A.M., D.A.F., J.A.S., J.L.Q.), the Department of Thoracic Surgery, Glenfield Hospital (A.N., S.R.), and the Medical Research Center Toxicology Unit (J.L.Q.), Leicester, the Institute of Cancer Studies, University of Manchester (F.B.), the Christie Hospital (F.B., Y.S.), the Departments of Cardiothoracic Surgery (R.S.) and Pathology (L.J., A.M.Q.) and the North West Lung Centre (P.A.C.), University Hospital of South Manchester, and Cancer Research UK Manchester Institute (C.D.), Manchester, the Departments of Thoracic Surgery (B.N.) and Cellular Pathology (G.L., S. Trotter), Birmingham Heartlands Hospital, Molecular Pathology Diagnostic Services, Queen Elizabeth Hospital (P.T., B.O.), and Institute of Immunology and Immunotherapy, University of Birmingham (G.M.), Birmingham, the Departments of Medical Oncology (M.N.), Cardiothoracic Surgery (H.R.), Pathology (K.K.), Respiratory Medicine (M.C.), and Radiology (L.G.), Aberdeen University Medical School and Aberdeen Royal Infirmary, Aberdeen, the Department of Respiratory Medicine, Barnet and Chase Farm Hospitals, Barnet (S. Khan), the Department of Respiratory Medicine, Princess Alexandra Hospital, Harlow (P.R.), the Department of Clinical Oncology, St. Luke's Cancer Centre, Guildford (V.E.), the Departments of Pathology (B.I.), Respiratory Medicine (M.I.-S.), and Radiology (V.P.), Ashford and St. Peters' Hospitals, Surrey, the Department of Clinical Oncology, Velindre Hospital (J.F.L.), the Departments of Radiology (H.A.) and Respiratory Medicine (H.D.), University Hospital Llandough, the Departments of Pathology (R.A.) and Cardiothoracic Surgery (M.K.), University Hospital of Wales, and Cardiff University (R.A.), Cardiff, and Wellcome Trust Sanger Institute, Hinxton, and Big Data Institute, University of Oxford, Oxford (S.D.) - all in the United Kingdom; the Center for Biological Sequence Analysis, Department of Systems Biology, Technical University of Denmark, Lyngby (Z.S.); the Computational Health Informatics Program, Boston Children's Hospital and Harvard Medical School, Boston (Z.S.); MTA-SE-NAP, Brain Metastasis Research Group, 2nd Department of Pathology, Semmelweis University, Budapest, Hungary (Z.S.); Berlin Institute for Medical Systems Biology, Max Delbrueck Center for Molecular Medicine, Berlin (R.F.S.); and the Department of Human Genetics, University of Leuven, Leuven, Belgium (P.V.L.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1616288DOI Listing
June 2017

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

J Clin Oncol 2017 Apr 21;35(12):1288-1296. Epub 2017 Feb 21.

James Chih-Hsin Yang and Chia-Chi Lin, National Taiwan University Hospital, Taipei; Wu-Chou Su, National Cheng Kung University Hospital, Tainan, Taiwan, Republic of China; Myung-Ju Ahn, Sungkyunkwan University; Dong-Wan Kim, Seoul National University Hospital; Sang-We Kim, Asan Medical Center, Seoul; Joo-Hang Kim, CHA University, Gyeonggi-do, Republic of Korea; Suresh S. Ramalingam, Emory University School of Medicine, Atlanta, GA; Lecia V. Sequist, Massachusetts General Hospital; Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA; David Planchard, Institut Gustave Roussy, Villejuif, France; Enriqueta Felip, Vall d'Hebron University Hospital, Barcelona, Spain; Fiona Blackhall, The Christie Hospital; University of Manchester, Manchester; Helen Mann and Serban Ghiorghiu, AstraZeneca, Cambridge; Mireille Cantarini, AstraZeneca, Macclesfield, United Kingdom; Daniel Haggstrom, Carolinas Healthcare System, Charlotte, NC; Kiyotaka Yoh, National Cancer Center Hospital East, Kashiwa, Chiba; Tomonori Hirashima, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan; Silvia Novello, University of Turin, Turin, Italy; and Kathryn Gold, University of California San Diego Moores Cancer Center, San Diego, CA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.70.3223
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.70.3223DOI Listing
April 2017

Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET).

J Clin Oncol 2017 Feb 28;35(4):402-411. Epub 2016 Nov 28.

Siow Ming Lee, Mary Falzon, Martin Forster, Arrigo Capitanio, Robin Rudd, Natasha Iles, Yenting Ngai, Michael Gandy, Rachel Lillywhite, and Allan Hackshaw, University College London, University College London Hospitals; James Spicer, Guy's and St Thomas's NHS Foundation Trust; Conrad Lewanski, Charing Cross Hospital, London; Fiona Blackhall, The Christie NHS Foundation Trust, Manchester; Marianne Nicolson, Aberdeen Royal Infirmary, Aberdeen; Abhro Chaudhuri, Lincoln County Hospital, Lincoln; Gary Middleton, University of Birmingham, Birmingham; Samreen Ahmed, Leicester Royal Infirmary, Leicester; Jonathan Hicks, New Victoria Hospital, Kingston Upon Thames; Barbara Crosse, Calderdale and Huddersfield NHS Foundation Trust, Huddersfield; Mark Napier, North Devon District Hospital, Barnstaple; Julian M. Singer, Princess Alexandra Hospital NHS Foundation Trust, Harlow; David Ferry, New Cross Hospital, Wolverhampton; and Sally-Ann Rolls, Withybush General Hospital, Haverfordwest, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.1841DOI Listing
February 2017

Assessment of Breathlessness in Lung Cancer: Psychometric Properties of the Dyspnea-12 Questionnaire.

J Pain Symptom Manage 2017 02 5;53(2):208-215. Epub 2016 Oct 5.

School of Nursing, Midwifery and Social Work, University of Manchester, Manchester, United Kingdom; School of Nursing, The Hong Kong Polytechnic University, Kowloon, Hong Kong.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpainsymman.2016.08.009DOI Listing
February 2017

Circulating Tumor Cells Detected in the Tumor-Draining Pulmonary Vein Are Associated with Disease Recurrence after Surgical Resection of NSCLC.

J Thorac Oncol 2016 10 25;11(10):1793-7. Epub 2016 Jul 25.

Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, Manchester, United Kingdom; Cancer Research UK Lung Cancer Centre of Excellence, Manchester, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.06.017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063509PMC
October 2016

Selumetinib in the treatment of non-small-cell lung cancer.

Future Oncol 2016 Nov 28;12(22):2545-2560. Epub 2016 Jul 28.

The Christie NHS Foundation Trust, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2016-0132DOI Listing
November 2016

Current status of immunotherapy for non-small-cell lung cancer.

Tumori 2016 Aug 21;102(4):337-51. Epub 2016 Jul 21.

Institute of Cancer Sciences, Manchester University and The Christie NHS Foundation Trust, Manchester - UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5301/tj.5000537DOI Listing
August 2016

Identification and Targeting of Long-Term Tumor-Propagating Cells in Small Cell Lung Cancer.

Cell Rep 2016 07 30;16(3):644-56. Epub 2016 Jun 30.

Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2016.06.021DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4956576PMC
July 2016

Inhibition of PI3K/BMX Cell Survival Pathway Sensitizes to BH3 Mimetics in SCLC.

Mol Cancer Ther 2016 06 29;15(6):1248-60. Epub 2016 Mar 29.

Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, United Kingdom. CRUK Lung Cancer Centre of Excellence, Manchester, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-15-0885DOI Listing
June 2016

Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?

Drugs 2016 May;76(8):831-40

Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester, M20 4BX, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-016-0578-zDOI Listing
May 2016

Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.

J Clin Oncol 2016 08 28;34(24):2858-65. Epub 2016 Mar 28.

Benjamin J. Solomon, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Federico Cappuzzo, Istituto Toscano Tumori, Livorno; Jolanda Paolini, Jennifer Tursi, and Tiziana Usari, Pfizer Oncology, Milan, Italy; Enriqueta Felip, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain; Fiona H. Blackhall, The Christie Hospital and Institute of Cancer Sciences, Manchester University, Manchester, United Kingdom; Daniel B. Costa, Beth Israel Deaconess Center, Boston, MA; Tarek Mekhail, Florida Hospital Cancer Institute, Orlando, FL; Keith D. Wilner and Paulina Selaru, Pfizer Oncology, La Jolla, CA; Dong-Wan Kim, Seoul National University Hospital, Seoul, South Korea; Kazuhiko Nakagawa, Kinki University, Osaka, Japan; Yi-Long Wu, Guangdong Lung Cancer Institute, Guangzhou, China; and Tony S.K. Mok, State Key Laboratory of South China, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Shatin, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.5888DOI Listing
August 2016

Development of a circulating miRNA assay to monitor tumor burden: From mouse to man.

Mol Oncol 2016 Feb 28;10(2):282-91. Epub 2015 Oct 28.

Clinical & Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2015.10.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4750526PMC
February 2016

Discovery and Validation of Predictive Biomarkers of Survival for Non-small Cell Lung Cancer Patients Undergoing Radical Radiotherapy: Two Proteins With Predictive Value.

EBioMedicine 2015 Aug 19;2(8):841-50. Epub 2015 Jun 19.

Stoller Biomarker Discovery Centre, Manchester Academic Health Science Centre, The University of Manchester, Wolfson Molecular Imaging Centre, Manchester M20 3LJ, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2015.06.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4563120PMC
August 2015

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

N Engl J Med 2014 Dec;371(23):2167-77

From Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.); State Key Laboratory of South China, Hong Kong Cancer Institute, Department of Clinical Oncology, Chinese University of Hong Kong, Shatin (T. Mok), and Guangdong Lung Cancer Institute, Guangzhou (Y.-L.W.) - both in China; Seoul National University Hospital, Seoul, South Korea (D.-W.K.); Kinki University, Osaka, Japan (K.N.); Florida Hospital Cancer Institute, Orlando (T. Mekhail); Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona (E.F.); Istituto Toscano Tumori, Livorno (F.C.), and Pfizer Oncology, Milan (J.P., T.U., J.T.) - both in Italy; Pfizer Oncology (S.I.) and Pfizer Global Innovative Pharma Business (A.R.) - both in New York; Pfizer Oncology, La Jolla, CA (K.D.W.); and the Christie Hospital and Institute of Cancer Sciences, Manchester University, Manchester, United Kingdom (F.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1408440DOI Listing
December 2014

Evaluation of antitumor activity using change in tumor size of the survivin antisense oligonucleotide LY2181308 in combination with docetaxel for second-line treatment of patients with non-small-cell lung cancer: a randomized open-label phase II study.

J Thorac Oncol 2014 Nov;9(11):1704-8

*Cedars-Sinai Medical Center, Los Angeles, California; †The Lung Cancer Group, The Christie and University Hospital of South Manchester, Manchester, United Kingdom; ‡Memorial Cancer Centre of Oncology and Institute Department of Lung Cancer and Chest Tumours, Warsaw, Poland; §Poznań University of Medical Sciences, Wielkopolskie Centrum Pulmonologii i Torakochirurgii, Poznań, Poland; ‖Karmanos Cancer Center, Detroit, Michigan; ¶Lung Cancer Unit, IRCCS AOU San Martino IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy; #Gemeinschaftspraxis für Haematologie, Onkologie und Palliativmedizin, Münster, Germany; **Department of Thoracic Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida; ††St. Vincentius-Kliniken gAG - Med. Klinik Abt. 2, Karlsruhe, Germany; ‡‡Sheffield Experimental Cancer Medicine Centre, Academic Unit of Clinical Oncology, University of Sheffield, Weston Park Hospital, Sheffield, United Kingdom; §§Internal Medicine, Karmanos Cancer Institute, Detroit, Michigan; ‖‖Eli Lilly and Company, Windlesham, United Kingdom; ¶¶Eli Lilly and Company, Basingstoke, Hampshire, United Kingdom; ##Eli Lilly and Company, Indianapolis, Indiana; and ***Department of Oncology, University of Oxford, Cancer and Haematology Center, Churchill Hospital, Oxford, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000285DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340255PMC
November 2014

Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters.

J Thorac Oncol 2014 Nov;9(11):1675-84

*Centre Hospitalier Universitaire de Vaud, Lausanne, Switzerland; †Division of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland; ‡Frontier Science Foundation-Hellas & University of Athens, Athens, Greece; §Aberdeen Royal Infirmary, Aberdeen, United Kingdom; ‖Institute for Pathology, University Hospital Basel, Basel, Switzerland; ¶Department of Oncology, University Hospital, Aarhus, Denmark; #Department of Medical Oncology, St. James's Hospital, Dublin, Ireland; **Medical University of Gdansk, Gdansk, Poland; ††University Hospital KU Leuven, Leuven, Belgium; ‡‡Vall d'Hebron University Hospital, Barcelona, Spain; §§Center of Predictive Molecular Medicine, University Foundation, Chieti, Italy; ‖‖Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China; ¶¶VU University Medical Center, Amsterdam, Netherlands; ##Maastricht University Medical Centre, Maastricht, Netherlands; ***Manchester University and The Christie National Health Services Foundation Trust, Manchester, United Kingdom; †††Netherlands Cancer Institute, Amsterdam, Netherlands; ‡‡‡Department of Medicine, University of Valencia and Department of Medical Oncology, General University Hospital of Valencia, Valencia, Spain; §§§Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain; and ‖‖‖Clinic of Oncology, University Hospital Zurich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000320DOI Listing
November 2014

Patient-reported outcomes and quality of life in PROFILE 1007: a randomized trial of crizotinib compared with chemotherapy in previously treated patients with ALK-positive advanced non-small-cell lung cancer.

J Thorac Oncol 2014 Nov;9(11):1625-33

*Department of Medical Oncology, Institute of Cancer Sciences, Manchester University, and Christie Hospital NHS Foundation Trust, Manchester, United Kingdom; †Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea; ‡Department of Thoracic Oncology, Institut Gustave Roussy, Villejuif, France; §National Cancer Center Hospital, Tokyo, Japan; ‖Division of Translational & Clinical Research, Center for Lung Cancer, National Cancer Center, Goyang, South Korea; ¶Clinical Development, Pfizer Oncology, La Jolla, CA; #Biostatistics, Pfizer Global Innovative Pharma Business, New York, NY; **Global Outcomes & Evidence, Pfizer Oncology, New York, NY; ††Department of Oncology, McGill University Health Centre, Montreal, Canada; and ‡‡Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000318DOI Listing
November 2014

Motesanib plus carboplatin/paclitaxel in patients with advanced squamous non-small-cell lung cancer: results from the randomized controlled MONET1 study.

J Thorac Oncol 2014 Aug;9(8):1154-61

*Department of Oncology, University of Turin, San Luigi Hospital, Turin, Italy; †Thoracic Surgery Department, Zaporizhzhya State Medical University, Zaporizhzhya, Ukraine; ‡Sumy Regional Oncology Centre, Sumy State University, Sumy, Ukraine; §Centrul de Oncologie Medicala, Iasi, Romania; ‖Central Hospital Bad Berka, Bad Berka, Germany; ¶Department of Medical Oncology, The Christie National Health Services Foundation Trust, Manchester, United Kingdom; #Department of Biostatistics & Epidemiology, Amgen Inc., South San Francisco; **Department of Oncology, Amgen Inc., Thousand Oaks, CA; and ††Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000227DOI Listing
August 2014

Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project.

J Clin Oncol 2014 Sep 28;32(25):2780-7. Epub 2014 Jul 28.

Fiona H. Blackhall and Daisuke Nonaka, Manchester University and The Christie National Health Services Foundation Trust, Manchester; Keith M. Kerr, Aberdeen University Medical School, Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Solange Peters and Igor Letovanec, Centre Hospitalier Universitaire Vaudois, Lausanne; Lukas Bubendorf and Spasenija Savic, Institute for Pathology, University Hospital Basel, Basel; Alex Soltermann and Rolf A. Stahel, University Hospital Zurich, Zurich, Switzerland; Urania Dafni, Frontier Science Foundation-Hellas and University of Athens, Athens, Greece; Henrik Hager, University Hospital, Aarhus, Denmark; Kenneth J. O'Byrne, St James's Hospital, Dublin, Ireland; Christoph Dooms, University Hospital KU Leuven, Leuven, Belgium; Aleksandra Sejda, Medical University of Gdansk, Gdansk, Poland; Javier Hernández-Losa, Vall d'Hebron University Hospital, Barcelona; Miguel Martorell, Universitat de Valencia and Hospital General Universitario de Valencia, Valencia; Rafael Rosell, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain; Antonio Marchetti, Center of Predictive Molecular Medicine, University Foundation, Chieti, Italy; Qiang Tan, Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China; Erik Thunnissen, VU University Medical Clinic Center; Jeroen de Jong, Netherlands Cancer Institute, Amsterdam; Ernst-Jan M. Speel, Maastricht University Medical Centre, Maastricht, the Netherlands; and Richard Cheney, Roswell Park Cancer Institute, Buffalo, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.54.5921DOI Listing
September 2014

Tracking genomic cancer evolution for precision medicine: the lung TRACERx study.

PLoS Biol 2014 Jul 8;12(7):e1001906. Epub 2014 Jul 8.

Translational Cancer Therapeutics Laboratory, University College London Cancer Institute, London, United Kingdom; Department of Medical Oncology, University College London Hospitals, London, United Kingdom; Translational Cancer Therapeutics Laboratory, London Research Institute, London, United Kingdom.

View Article

Download full-text PDF

Source
http://orbit.dtu.dk/files/101357162/Tracking_Genomic_Cancer.
Web Search
http://dx.plos.org/10.1371/journal.pbio.1001906
Publisher Site
http://dx.doi.org/10.1371/journal.pbio.1001906DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086714PMC
July 2014

Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial.

J Clin Oncol 2014 Jun 28;32(18):1882-8. Epub 2014 Apr 28.

Anna Spathis and Kate Fife, Cambridge University Hospitals National Health Service (NHS) Foundation Trust, Cambridge; Fiona Blackhall, The Christie NHS Foundation Trust and University of Manchester, Manchester; Susan Dutton, Ronja Bahadori, Rose Wharton, and Bee Wee, University of Oxford; Bee Wee, Sir Michael Sobell House, Oxford; Mary O'Brien, Royal Marsden Hospital; Patrick Stone, St George's University of London; Tim Benepal, St George's Hospital NHS Trust, London; and Nick Bates, Buckinghamshire Healthcare NHS Trust, Aylesbury, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.54.4346DOI Listing
June 2014

Early reduction in tumour [18F]fluorothymidine (FLT) uptake in patients with non-small cell lung cancer (NSCLC) treated with radiotherapy alone.

Eur J Nucl Med Mol Imaging 2014 Apr 7;41(4):682-93. Epub 2014 Feb 7.

Institute of Population Health, Wolfson Molecular Imaging Centre, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, M20 3LJ, UK,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-013-2632-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955141PMC
April 2014

Molecular analysis of circulating tumour cells-biology and biomarkers.

Nat Rev Clin Oncol 2014 Mar 21;11(3):129-44. Epub 2014 Jan 21.

Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester and Manchester Cancer Research Centre, 550 Wilmslow Road, Manchester M20 4BX, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2013.253DOI Listing
March 2014

How can we optimise concurrent chemoradiotherapy for inoperable stage III non-small cell lung cancer?

Lung Cancer 2014 Feb 1;83(2):117-25. Epub 2013 Dec 1.

Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK; Radiotherapy Related Research, The Christie NHS Foundation Trust, Manchester, United Kingdom. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2013.11.017DOI Listing
February 2014

Prognostic and predictive biomarkers in early stage NSCLC: CTCs and serum/plasma markers.

Transl Lung Cancer Res 2013 Oct;2(5):382-97

Clinical and Experimental Pharmacology Group, Paterson Institute for Cancer Research, University of Manchester, M20 4BX, UK ; ; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, M20 4BX, UK.

View Article

Download full-text PDF

Source
http://www.tlcr.org/article/view/1611
Publisher Site
http://dx.doi.org/10.3978/j.issn.2218-6751.2013.09.02DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367728PMC
October 2013

Clinical utility of circulating tumour cell detection in non-small-cell lung cancer.

Curr Treat Options Oncol 2013 Dec;14(4):610-22

Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Withington, Manchester, M20 4BX, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-013-0253-5DOI Listing
December 2013

Treatment and detection of ALK-rearranged NSCLC.

Lung Cancer 2013 Aug 12;81(2):145-54. Epub 2013 Jun 12.

Department of Oncology, University Hospital of Vaudois (CHUV), Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2013.03.017DOI Listing
August 2013

The impact on the multidisciplinary team of molecular profiling for personalized therapy in non-small cell lung cancer.

Lung Cancer 2013 Feb 22;79(2):101-3. Epub 2012 Nov 22.

Department of Medical Oncology, Christie Hospital, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2012.10.016DOI Listing
February 2013

Variant Ciz1 is a circulating biomarker for early-stage lung cancer.

Proc Natl Acad Sci U S A 2012 Nov 16;109(45):E3128-35. Epub 2012 Oct 16.

Cizzle Biotech, University of York, Yorkshire YO10 5DD, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1210107109DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494940PMC
November 2012

Liquid chromatography-mass spectrometry calibration transfer and metabolomics data fusion.

Anal Chem 2012 Nov 29;84(22):9848-57. Epub 2012 Oct 29.

School of Chemistry, Manchester Institute of Biotechnology, University of Manchester, 131 Princess Street, Manchester, M1 7DN, United Kingdom.

View Article

Download full-text PDF

Source
http://pubs.acs.org/doi/10.1021/ac302227c
Publisher Site
http://dx.doi.org/10.1021/ac302227cDOI Listing
November 2012

Biology and clinical relevance of circulating tumour cells.

J Thorac Dis 2012 Oct;4(5):453-5

Clinical and Experimental Pharmacology Group, Paterson institute for Cancer Research, Manchester, UK;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2072-1439.2012.09.02DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461082PMC
October 2012

The Manchester cough in lung cancer scale: the development and preliminary validation of a new assessment tool.

J Pain Symptom Manage 2013 Feb 25;45(2):179-90. Epub 2012 Aug 25.

School of Nursing, Midwifery & Social Work, University of Manchester, Manchester, United Kingdom.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S088539241200271
Publisher Site
http://dx.doi.org/10.1016/j.jpainsymman.2012.01.015DOI Listing
February 2013